These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24198049)

  • 1. Treatment and impact of dyslipidemia in diabetic nephropathy.
    Toyama T; Shimizu M; Furuichi K; Kaneko S; Wada T
    Clin Exp Nephrol; 2014 Apr; 18(2):201-5. PubMed ID: 24198049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
    Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.
    Gonzalez GL; Manrique CM; Sowers JR
    J Cardiometab Syndr; 2006; 1(3):178-83. PubMed ID: 17679817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipids and diabetic renal disease.
    Cooper ME; Jandeleit-Dahm KA
    Curr Diab Rep; 2005 Dec; 5(6):445-8. PubMed ID: 16316596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.
    Chen SC; Tseng CH
    Rev Diabet Stud; 2013; 10(2-3):88-100. PubMed ID: 24380085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of statins on the kidneys in patients with type 2 diabetes.
    Hanai K; Babazono T; Uchigata Y
    Clin Exp Nephrol; 2017 Aug; 21(4):633-642. PubMed ID: 27631405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of statins in managing diabetic dyslipidemia.
    Toth PP
    J Fam Pract; 2010 May; 59(5 Suppl):S23-9. PubMed ID: 20544054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
    Athyros VG; Tziomalos K; Karagiannis A
    Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy of diabetic dyslipidemia: do the statins suffice?
    Mooradian AD
    Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease].
    Monhart V
    Vnitr Lek; 2009; 55(7-8):671-8. PubMed ID: 19731874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials.
    Hung CC; Tsai JC; Kuo HT; Chang JM; Hwang SJ; Chen HC
    Rev Diabet Stud; 2013; 10(2-3):110-20. PubMed ID: 24380087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Shen X; Zhang Z; Zhang X; Zhao J; Zhou X; Xu Q; Shang H; Dong J; Liao L
    Lipids Health Dis; 2016 Oct; 15(1):179. PubMed ID: 27733168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of dyslipidemia in diabetic CKD patients].
    Massy ZA; Andréjak M
    Nephrol Ther; 2006 Jan; 2 Suppl 1():S49-52. PubMed ID: 17378140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipids and diabetic nephropathy.
    Rosario RF; Prabhakar S
    Curr Diab Rep; 2006 Dec; 6(6):455-62. PubMed ID: 17118229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
    Baba T; Neugebauer S; Watanabe T
    Drugs; 1997 Aug; 54(2):197-234. PubMed ID: 9257079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Park J
    Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.
    Fujii M; Inoguchi T; Maeda Y; Sasaki S; Sawada F; Saito R; Kobayashi K; Sumimoto H; Takayanagi R
    Kidney Int; 2007 Aug; 72(4):473-80. PubMed ID: 17568784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.